What is Norgine?
Headquartered in The Netherlands, Norgine has dedicated over a century to the development and distribution of innovative medicines. As a specialist pharmaceutical entity, its core business revolves around identifying unmet medical needs and bringing effective therapeutic solutions to market. The company's longevity is a testament to its adaptive strategies and consistent delivery of value within the highly regulated and competitive healthcare industry. Norgine's operational model emphasizes a deep understanding of patient needs and a commitment to scientific advancement.
How much funding has Norgine raised?
Norgine has raised a total of $12.1M across 1 funding round:
Other Financing Round
$12.1M
Other Financing Round (2016): $12.1M, investors not publicly disclosed
What's next for Norgine?
With a substantial funding history and a recent capital injection, Norgine is strategically positioned for continued expansion and innovation. The enterprise-level funding suggests a focus on scaling operations, potentially through further research and development, strategic acquisitions, or expanding market reach into new territories. The company's long-standing presence in the pharmaceutical sector indicates a mature lifecycle stage, likely focused on consolidating its market position and leveraging its established infrastructure to drive future growth and maintain its leadership in delivering specialized medical treatments.
See full Norgine company page
